CareFusion responds to media story regarding a CareFusion-funded clinical study

#IVTEAM #Intravenous products: CareFusion report “Our products are safe and effective. In particular, our skin prep product, ChloraPrep, has been proven effective when used in conjunction with best clinical practices to effectively kill microorganisms prior to surgery or injection. The active agents in ChloraPrep, chlorhexidine gluconate (CHG) in combination with isopropyl alcohol, have been acknowledged for years by multiple independent clinical organizations, including the Centers for Disease Control and Prevention, as a superior agent in prepping skin prior to an invasive procedure. There is a large body of evidence supporting these recommendations that has been published, peer reviewed and recognized by some of the best scientific minds in the world.

A recent news report included the unsubstantiated allegations of a former employee about a CareFusion-funded clinical study published in the New England Journal of Medicine. The government investigated the matter and did not take action on the former employee’s allegations related to the study or its validity. The settlement agreement announced by the government and CareFusion on January 9 did not pertain to the clinical study or its analysis.”